EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder

Andrea Cipriani, Karen Barros Parron Fernandes, Benoit H Mulsant, Orestis Efthimiou, Nicola Williams, Sam Mort, Rania Elgarf, Qiang Liu, Nyla Haque, Jennifer Potts, Roger Ede, Robin Fox und 19 weitere

JAMA · 14.04.2026 · 335 (14) · 1219

DOI: 10.1001/jama.2026.1327 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA, erschienen am 14.04.2026. Verfasst von Andrea Cipriani und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Oxford, Oxford, England. Hauptthemen laut MEDLINE: Antidepressive Agents, Decision Support Systems, Clinical, Generalized Anxiety Disorder, Major Depressive Disorder. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Antidepressants for moderate to severe major depressive disorder may be discontinued prematurely because the prescribed antidepressant is not always the most appropriate medication for an individual. Guidelines have recommended more precise targeting of antidepressant treatment.

Objective

To evaluate the efficacy of a web-based tool to personalize antidepressant treatment. Design, Setting, and Participants This multicenter, randomized clinical trial included persons between the ages of 18 and 74 years with major depressive disorder. The trial was conducted at 47 sites in 3 countries (Brazil, Canada, and the UK). The first participant was screened on November 29, 2022, and the last follow-up visit occurred on January 15, 2025.

Intervention

A total of 540 participants were randomized (1:1) to an evidence-based clinical decision-support system (PETRUSHKA tool; n = 271) or usual care (n = 269). Main Outcomes and Measures The primary outcome was treatment discontinuation due to any cause at 8 weeks. The secondary outcomes included treatment discontinuation up to 24 weeks due to adverse events and changes in depressive symptoms (measured with the 9-item Patient Health Questionnaire [PHQ-9]; range, 0-27; higher scores indicate more severe depression) and anxiety symptoms (measured with the 7-item Generalized Anxiety Disorder [GAD-7] questionnaire; range, 0-21; higher scores indicate more severe symptoms).

Results

Of the 520 eligible participants, 493 were included in the primary analysis (median age, 35 [IQR, 25 to 48] years; 58% female; PHQ-9 mean score, 16.6 [SD, 5.1]; GAD-7 mean score, 11.5 [SD, 4.1]). At 8 weeks, 41 of 241 participants (17%) in the PETRUSHKA group discontinued the prescribed antidepressant due to any cause vs 69 of 252 (27%) in the usual care group (adjusted relative risk, 0.62 [95% CI, 0.44 to 0.88]; P = .007). At 8 weeks, 22 of 241 participants (9%) in the PETRUSHKA group discontinued the prescribed antidepressant due to adverse events vs 39 of 252 (16%) in the usual care group (adjusted relative risk, 0.59 [95% CI, 0.36 to 0.97]; P = .04). For the assessment of depressive symptoms at 24 weeks, the mean PHQ-9 score was 7.1 (SD, 5.4) in the PETRUSHKA group vs 9.2 (SD, 6.5) in the usual care group (n = 129 in each group; adjusted between-group mean difference, −1.92 [95% CI, −3.06 to −0.78]; P < .001). For the assessment of anxiety symptoms at 24 weeks, the mean GAD-7 score was 4.6 (SD, 4.1) in the PETRUSHKA group (n = 133) vs 5.8 (SD, 4.9) in the usual care group (n = 126) (adjusted between-group mean difference, −1.39 [95% CI, −2.26 to −0.52]; P = .002). Conclusions and Relevance Compared with usual care, use of the PETRUSHKA tool increased the number of patients still taking their antidepressant at 8 weeks and improved depressive and anxiety symptoms at 24 weeks. However, lack of a double-blind design and the large amount of missing data limit the validity of these results. Trial Registration ClinicalTrials.gov Identifier: NCT05608330

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antidepressive AgentsDecision Support Systems, ClinicalGeneralized Anxiety DisorderMajor Depressive DisorderAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultFollow-Up StudiesPatient Health QuestionnaireSeverity of Illness IndexTreatment Outcome

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry, University of Oxford, Oxford, England.
  • Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, England.
  • NIHR Oxford Health Clinical Research Facility, Oxford Health NHS Foundation Trust, Oxford, England.
  • School of Medicine, Pontifícia Universidade Católica do Paraná, Londrina, Brazil.
  • Graduate Program of Health Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.
  • Department of Psychiatry, Temerty School of Medicine, University of Toronto, Toronto, Ontario, Canada.

Zitieren

APA

Cipriani, A., Fernandes, K. B. P., Mulsant, B. H., Efthimiou, O., Williams, N., Mort, S., Elgarf, R., Liu, Q., Haque, N., Potts, J., Ede, R., Fox, R., Liboni, M., Nesi Cavicchioli, D. A., Simon, J., Smith, K. A., Zangani, C., Li, Z., Taylor, U., …, & PETRUSHKA Team (2026). A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder. JAMA, 335(14), 1219. https://doi.org/10.1001/jama.2026.1327

Vancouver

Cipriani A, Fernandes KBP, Mulsant BH, Efthimiou O, Williams N, Mort S, et al. A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder. JAMA. 2026;335(14):1219. doi:10.1001/jama.2026.1327

BibTeX
@article{Cipriani2026,
  author = {Cipriani, Andrea and Fernandes, Karen Barros Parron and Mulsant, Benoit H and Efthimiou, Orestis and Williams, Nicola and Mort, Sam and Elgarf, Rania and Liu, Qiang and Haque, Nyla and Potts, Jennifer and Ede, Roger and Fox, Robin and Liboni, Marcos and Nesi Cavicchioli, Diego A and Simon, Judit and Smith, Katharine A and Zangani, Caroline and Li, Zhenpeng and Taylor, Ursula and Husain, M Ishrat and Cipriani, Maddalena and Carpaneze Dalaqua, Paulo V and Leite, Eduardo Fernandes and Aliano Gâmbaro, Gustavo and Nabhan Silveira, Diogo and Manfredin Vila, Luísa and Liboni Cavicchioli, Fernanda and Furukawa, Toshi A and Naci, Huseyin and Ostinelli, Edoardo G and PETRUSHKA Team, PETRUSHKA Team},
  title = {A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {14},
  pages = {1219},
  doi = {10.1001/jama.2026.1327}
}
Kostenlos starten →